GGA3 · Western blot design guide

GGA3 Western Blot Planning Guide

Plan a GGA3 Western blot around the catalog-observed 78.3 kDa band, image-backed A03641-2 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for GGA3 (GGA3): expected band 78.3 kDa, antibody A03641-2, and guide-derived SDS-PAGE protocol steps
GGA3 Western blot protocol sheet — expected band 78.3 kDa, antibody A03641-2, controls and PMC citations. Open the full GGA3 WB guide →

GGA3 Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 78.3 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Cerebellum
Negative control ⓘ Smooth muscle
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 78.3 kDa
ⓘ Localization Golgi apparatus, trans-Golgi network membrane / Endosome membrane
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated GGA3 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateCerebellum
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA03641-2 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected GGA3 Western Blot Band Size?

Use the product-observed 78.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
78.3 kDaMatches the authoritative product WB observation.
78.3 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected GGA3 appearancePlan around 78.3 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band78.3 kDa; use this as the primary experimental expectation.
Calculated mass78.3 kDa from UniProt Q9NZ52; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A03641-2.
Why is my band missing or off?
SituationLikely causeNext action
78.3 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for GGA3 Western blot

🧪Use Cerebellum as the first positive-control candidate and Smooth muscle as the HPA Not detected negative candidate.
Positive control: Cerebellum (High)
Negative control: Smooth muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for GGA3

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Cerebellum Reported tissue cells High Protein (HPA) HPA →
Colon Reported tissue cells High Protein (HPA) HPA →
Kidney Reported tissue cells High Protein (HPA) HPA →
Pancreas Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Smooth muscle Reported tissue cells Not detected Protein (HPA) HPA →
Soft tissue Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced GGA3 Western Blot Tips

Deeper troubleshooting and optimisation questions for GGA3, answered from its protein features.

Which band should guide the blot?
Use 78.3 kDa, the observation attached to the authoritative A03641-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 78.3 kDa expectation.
Which positive control should I start with?
Start with Cerebellum, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Smooth muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for GGA3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03641-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

GGA3 Western Blot Reagents

Human-reactive GGA3 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for GGA3 using A03641-2; observed band 78.3 kDa
Anti-GGA3 Antibody Picoband®
Cat # A03641-2

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q9NZ52
  2. Human Protein Atlas — GGA3
  3. A03641-2 product record
  4. PMC8798021 — Up-regulated GGA3 promotes non-small cell lung cancer proliferation by regulating TrkA receptor (Translational cancer research, 2019)
  5. PMC12278334 — ARF1-Related Diseases in China: The Initial Study of Phenotype and Molecular Profile (Journal of cellular and molecular medicine, 2025)